What's Happening?
Draig Therapeutics has appointed Ivana Magovčević-Liebisch as its new President and CEO. Magovčević-Liebisch brings over 25 years of experience in the pharmaceutical and biotechnology industries, having
previously led Vigil Neuroscience. Her appointment follows the company's focus on developing treatments for neuropsychiatric diseases, including Major Depressive Disorder. Draig Therapeutics aims to leverage its expertise in modulating glutamate and GABA pathways to advance its pipeline of therapies.
Why It's Important?
The appointment of a seasoned leader like Magovčević-Liebisch is a strategic move for Draig Therapeutics as it seeks to advance its clinical-stage therapies. Her experience in growing biotech companies and advancing innovative treatments is expected to drive the company's mission to address unmet needs in neuropsychiatry. This leadership change could enhance Draig's position in the biotech industry and attract further investment and partnerships.
